EGFR and non-small cell lung carcinoma: Our finding that intermediate or high PD‐L1 expression (PD‐L1 TPS ≥20%) in patients with EGFR‐mutated NSCLC was a factor contributing to shorter PFS of osimertinib is meaningful for therapeutic strategy.